Search
Mangafodipir
go.drugbank.com/drugs/DB06796ApprovedInvestigationalWithdrawnManganese absorption into the tissues that makes the normal tissue appear brighter in MRI is limited in abnormal or cancerous tissue. … Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas.
Categories: Compounds used in a research, industrial, or household settingAcemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigationalit kept the same side effects. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSProducts: RASLACOF-XClascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigational[A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. … [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766]
Categories: Anti-Acne Preparations for Topical UseStiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigational[A19739] Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. … [A250825] However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalA combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024. … Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.
Categories: Antihypertensives for Pulmonary Arterial HypertensionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
go.drugbank.com/bio_entities/BE0005530TargetHumansInvolved in the regulation of synaptic function in excitatory hippocampal synapses. … May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue.
Synonyms: Mutated in multiple advanced cancers 1tRNA-dihydrouridine(20) synthase [NAD(P)+]-like
go.drugbank.com/bio_entities/BE0020091EnzymeHumansSpecifically modifies U20 in cytoplasmic tRNAs (PubMed:38680565). Activity depends on the presence of guanosine at position 19 in the tRNA substrate (PubMed:38680565). … Catalyzes the NADPH-dependent synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs (PubMed:15994936, PubMed:26429968, PubMed:30149704, PubMed:34798057, PubMed:38680565).
Synonyms: Up-regulated in lung cancer protein 8Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigationalLanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.
Categories: Drugs Used in Hereditary AngioedemaDatopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Categories: Topoisomerase I Inhibitors